Ipsens’ partner, Exelixis, announced phase 1 trial results for cabozantinib in combination with nivolumab in advanced genitourinary tumors

Logo Exelixis

Exelixis Announces Phase 1 Trial Results for Cabozantinib in Combination with Nivolumab in Advanced Genitourinary Tumors

October 07, 2016

Read the press release >

© Ipsen Pharma, 65 Quai Georges Gorse, 92100 Boulogne-Billancourt, France. All rights reserved. - 2019